Please enable JavaScript to continue using this application.

Compare $AUPH vs $ZYME | Chartloom

Compare

$AUPH vs $ZYME

Aurinia Pharmaceuticals Inc · Zymeworks Inc

AUPH

Aurinia Pharmaceuticals Inc

ZYME

Zymeworks Inc

Compare $AUPH vs $ZYME

Comparing Aurinia Pharmaceuticals Inc and Zymeworks Inc

AUPHAurinia Pharmaceuticals Inc

ZYMEZymeworks Inc

AUPHAurinia Pharmaceuticals Inc

Market cap

$2.14B

P/E (TTM)

7.08x

Forward P/E (NTM)

20.93x

Forward P/S (NTM)

6.14x

Rev growth (TTM)

19.8%

YTD performance

8.5%

52W performance

44.4%

FCF yield

8.2%

ZYMEZymeworks Inc

Market cap

$1.85B

P/E (TTM)

—

Forward P/E (NTM)

8.20x

Forward P/S (NTM)

3.91x

Rev growth (TTM)

-69.8%

YTD performance

-3.1%

52W performance

54.6%

FCF yield

-6.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AUPH

ZYME

Detailed metrics comparison

AUPH

Aurinia Pharmaceuticals Inc

ZYME

Zymeworks Inc

Market Cap

AUPH$2.14B

ZYME$1.85B

Enterprise Value

AUPH$2.02B

ZYME$1.92B

Price

AUPH$16.65

ZYME$25.79

P/E Ratio

AUPH7.08x

ZYMEN/A

P/S Ratio

AUPH6.87x

ZYME49.73x

EV/Sales

AUPH6.49x

ZYME51.70x

EV/EBITDA

AUPH10.34x

ZYME9.18x

P/B Ratio

AUPH3.43x

ZYME23.27x

P/FCF Ratio

AUPH12.23x

ZYMEN/A

EV/FCF

AUPH11.55x

ZYME-15.91x

PEG Ratio

AUPH0.02x

ZYMEN/A

Forward P/E (NTM)

AUPH20.93x

ZYME8.20x

Forward P/S (NTM)

AUPH6.14x

ZYME3.91x

Revenue (TTM)

AUPH$312M

ZYME$37M

Revenue Growth (YoY)

AUPH19.8%

ZYME-69.8%

Forward Rev Growth

AUPH17.6%

ZYME-15.2%

Gross Margin (TTM)

AUPH90.4%

ZYME0.0%

Operating Margin (TTM)

AUPH48.4%

ZYME0.0%

EBITDA Margin (TTM)

AUPH54.6%

ZYME-405.8%

Net Margin (TTM)

AUPH100.8%

ZYME-404.0%

FCF Margin (TTM)

AUPH56.2%

ZYME-325.1%

Net Income (TTM)

AUPH$314M

ZYME$-150M

FCF (TTM)

AUPH$175M

ZYME$-121M

EPS (TTM)

AUPH$2.35

ZYME-$2.05

ROE (TTM)

AUPH59.0%

ZYME-7207.0%

ROA (TTM)

AUPH45.0%

ZYME-3706.0%

ROIC (TTM)

AUPH52.4%

ZYME-4505.0%

Cash

AUPH$180M

ZYME$179M

Debt

AUPH$60M

ZYME$253M

Net Cash/Debt

AUPH$119M

ZYME$-73M

Current Ratio (TTM)

AUPH5.42x

ZYME6.32x

Quick Ratio (TTM)

AUPH4.86x

ZYME5.86x

Debt/Equity (TTM)

AUPH0.10x

ZYME3.14x

Debt/Assets (TTM)

AUPH0.0%

ZYME0.0%

Interest Coverage (TTM)

AUPHN/A

ZYMEN/A

Net Debt/EBITDA (TTM)

AUPH0.00x

ZYME0.00x

Beta

AUPH1.35

ZYME1.32

52W Performance

AUPH44.4%

ZYME54.6%

YTD Performance

AUPH8.5%

ZYME-3.1%

% from 52W High

AUPH-13.5%

ZYME-17.7%

% from 52W Low

AUPH52.7%

ZYME61.2%

Asset Turnover (TTM)

AUPH0.45x

ZYME0.09x

FCF Yield (TTM)

AUPH8.2%

ZYME-6.5%

Earnings Yield (TTM)

AUPH14.7%

ZYME-8.1%

Dividend Yield (TTM)

AUPHN/A

ZYMEN/A

Rule of 40

AUPH76.0

ZYME-394.8

EV/GP/RG

AUPH0.52

ZYMEN/A

Ticker research

View AUPH research View ZYME research

Metric	AUPH Aurinia Pharmaceuticals Inc	ZYME Zymeworks Inc
Market & Valuation
Market Cap	$2.14B	$1.85B
Enterprise Value	$2.02B	$1.92B
Price	$16.65	$25.79
P/E Ratio	7.08x	N/A
P/S Ratio	6.87x	49.73x
EV/Sales	6.49x	51.70x
EV/EBITDA	10.34x	9.18x
P/B Ratio	3.43x	23.27x
P/FCF Ratio	12.23x	N/A
EV/FCF	11.55x	-15.91x
PEG Ratio	0.02x	N/A
Forward P/E (NTM)	20.93x	8.20x
Forward P/S (NTM)	6.14x	3.91x
Revenue & Growth
Revenue (TTM)	$312M	$37M
Revenue Growth (YoY)	19.8%	-69.8%
Forward Rev Growth	17.6%	-15.2%
Profitability
Gross Margin (TTM)	90.4%	0.0%
Operating Margin (TTM)	48.4%	0.0%
EBITDA Margin (TTM)	54.6%	-405.8%
Net Margin (TTM)	100.8%	-404.0%
FCF Margin (TTM)	56.2%	-325.1%
Net Income (TTM)	$314M	$-150M
FCF (TTM)	$175M	$-121M
EPS (TTM)	$2.35	-$2.05
ROE (TTM)	59.0%	-7207.0%
ROA (TTM)	45.0%	-3706.0%
ROIC (TTM)	52.4%	-4505.0%
Financial Health
Cash	$180M	$179M
Debt	$60M	$253M
Net Cash/Debt	$119M	$-73M
Current Ratio (TTM)	5.42x	6.32x
Quick Ratio (TTM)	4.86x	5.86x
Debt/Equity (TTM)	0.10x	3.14x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.35	1.32
52W Performance	44.4%	54.6%
YTD Performance	8.5%	-3.1%
% from 52W High	-13.5%	-17.7%
% from 52W Low	52.7%	61.2%
Efficiency & Yields
Asset Turnover (TTM)	0.45x	0.09x
FCF Yield (TTM)	8.2%	-6.5%
Earnings Yield (TTM)	14.7%	-8.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	76.0	-394.8
EV/GP/RG	0.52	N/A
Ticker research	View AUPH research	View ZYME research

Valuation

P/E Ratio

AUPH

7.08x

P/S Ratio

AUPH

6.87x

ZYME

49.73x

EV/FCF

ZYME

-15.91x

AUPH

11.55x

Growth & revenue

Revenue Growth TTM

AUPH

19.8%

ZYME

-69.8%

Forward Revenue Growth

AUPH

17.6%

ZYME

-15.2%

Profitability & performance

Gross Margin

AUPH

90.4%

ZYME

0.0%

ROE

AUPH

59.0%

ZYME

-7207.0%

FCF Yield %

AUPH

8.2%

ZYME

-6.5%

52-Week Performance

ZYME

54.6%

AUPH

44.4%

Detailed metrics comparison

AUPH

Aurinia Pharmaceuticals Inc

ZYME

Zymeworks Inc

Market Cap

AUPH$2.14B

ZYME$1.85B

Enterprise Value

AUPH$2.02B

ZYME$1.92B

Price

AUPH$16.65

ZYME$25.79

P/E Ratio

AUPH7.08x

ZYMEN/A

P/S Ratio

AUPH6.87x

ZYME49.73x

EV/Sales

AUPH6.49x

ZYME51.70x

EV/EBITDA

AUPH10.34x

ZYME9.18x

P/B Ratio

AUPH3.43x

ZYME23.27x

P/FCF Ratio

AUPH12.23x

ZYMEN/A

EV/FCF

AUPH11.55x

ZYME-15.91x

PEG Ratio

AUPH0.02x

ZYMEN/A

Forward P/E (NTM)

AUPH20.93x

ZYME8.20x

Forward P/S (NTM)

AUPH6.14x

ZYME3.91x

Revenue (TTM)

AUPH$312M

ZYME$37M

Revenue Growth (YoY)

AUPH19.8%

ZYME-69.8%

Forward Rev Growth

AUPH17.6%

ZYME-15.2%

Gross Margin (TTM)

AUPH90.4%

ZYME0.0%

Operating Margin (TTM)

AUPH48.4%

ZYME0.0%

EBITDA Margin (TTM)

AUPH54.6%

ZYME-405.8%

Net Margin (TTM)

AUPH100.8%

ZYME-404.0%

FCF Margin (TTM)

AUPH56.2%

ZYME-325.1%

Net Income (TTM)

AUPH$314M

ZYME$-150M

FCF (TTM)

AUPH$175M

ZYME$-121M

EPS (TTM)

AUPH$2.35

ZYME-$2.05

ROE (TTM)

AUPH59.0%

ZYME-7207.0%

ROA (TTM)

AUPH45.0%

ZYME-3706.0%

ROIC (TTM)

AUPH52.4%

ZYME-4505.0%

Cash

AUPH$180M

ZYME$179M

Debt

AUPH$60M

ZYME$253M

Net Cash/Debt

AUPH$119M

ZYME$-73M

Current Ratio (TTM)

AUPH5.42x

ZYME6.32x

Quick Ratio (TTM)

AUPH4.86x

ZYME5.86x

Debt/Equity (TTM)

AUPH0.10x

ZYME3.14x

Debt/Assets (TTM)

AUPH0.0%

ZYME0.0%

Interest Coverage (TTM)

AUPHN/A

ZYMEN/A

Net Debt/EBITDA (TTM)

AUPH0.00x

ZYME0.00x

Beta

AUPH1.35

ZYME1.32

52W Performance

AUPH44.4%

ZYME54.6%

YTD Performance

AUPH8.5%

ZYME-3.1%

% from 52W High

AUPH-13.5%

ZYME-17.7%

% from 52W Low

AUPH52.7%

ZYME61.2%

Asset Turnover (TTM)

AUPH0.45x

ZYME0.09x

FCF Yield (TTM)

AUPH8.2%

ZYME-6.5%

Earnings Yield (TTM)

AUPH14.7%

ZYME-8.1%

Dividend Yield (TTM)

AUPHN/A

ZYMEN/A

Rule of 40

AUPH76.0

ZYME-394.8

EV/GP/RG

AUPH0.52

ZYMEN/A

Ticker research

View AUPH research View ZYME research

Metric	AUPH Aurinia Pharmaceuticals Inc	ZYME Zymeworks Inc
Market & Valuation
Market Cap	$2.14B	$1.85B
Enterprise Value	$2.02B	$1.92B
Price	$16.65	$25.79
P/E Ratio	7.08x	N/A
P/S Ratio	6.87x	49.73x
EV/Sales	6.49x	51.70x
EV/EBITDA	10.34x	9.18x
P/B Ratio	3.43x	23.27x
P/FCF Ratio	12.23x	N/A
EV/FCF	11.55x	-15.91x
PEG Ratio	0.02x	N/A
Forward P/E (NTM)	20.93x	8.20x
Forward P/S (NTM)	6.14x	3.91x
Revenue & Growth
Revenue (TTM)	$312M	$37M
Revenue Growth (YoY)	19.8%	-69.8%
Forward Rev Growth	17.6%	-15.2%
Profitability
Gross Margin (TTM)	90.4%	0.0%
Operating Margin (TTM)	48.4%	0.0%
EBITDA Margin (TTM)	54.6%	-405.8%
Net Margin (TTM)	100.8%	-404.0%
FCF Margin (TTM)	56.2%	-325.1%
Net Income (TTM)	$314M	$-150M
FCF (TTM)	$175M	$-121M
EPS (TTM)	$2.35	-$2.05
ROE (TTM)	59.0%	-7207.0%
ROA (TTM)	45.0%	-3706.0%
ROIC (TTM)	52.4%	-4505.0%
Financial Health
Cash	$180M	$179M
Debt	$60M	$253M
Net Cash/Debt	$119M	$-73M
Current Ratio (TTM)	5.42x	6.32x
Quick Ratio (TTM)	4.86x	5.86x
Debt/Equity (TTM)	0.10x	3.14x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.35	1.32
52W Performance	44.4%	54.6%
YTD Performance	8.5%	-3.1%
% from 52W High	-13.5%	-17.7%
% from 52W Low	52.7%	61.2%
Efficiency & Yields
Asset Turnover (TTM)	0.45x	0.09x
FCF Yield (TTM)	8.2%	-6.5%
Earnings Yield (TTM)	14.7%	-8.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	76.0	-394.8
EV/GP/RG	0.52	N/A
Ticker research	View AUPH research	View ZYME research